ZyVersa Therapeutics announces publication on NLRP3 inflammasome activation

ZyVersa Therapeutics announces publication of an article in the peer-reviewed journal, Clinical Immunology, demonstrating the role of inflammasome NLRP3 activation in lupus nephritis. In the paper titled, “Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis,” the authors evaluated renal biopsy tissue of patients with biopsy proven LN in comparison to control tissue. Data demonstrated that renal NLRP3 inflammasome activation positively correlated with LN severity and clinicopathological indices of LN. Following are key findings reported in the paper: Expression patterns of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 in the glomeruli and tubulointerstitum of LN patients were significantly higher in LN patients versus controls; Levels of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 were higher in patients with proliferative LN than in patients with non-proliferative LN; Levels of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 were positively correlated with several clinicopathological indices, including, proteinuria, renal pathological activity indices, and systemic lupus erythematosus disease activity index scores. The authors stated, “We comprehensively evaluated the activation patterns of the NLRP3 inflammasome pathway in the renal tissues of LN patients. NLRP3 was extensively activated in various renal intrinsic cells and infiltrating cells, and was closely associated with disease activity, which needs further explorations.”